TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27821398

Group type: EXPERIMENTAL
Intervention: Investigational product (IP) management through coordination of IP-related operations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coordination of IP supply activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education to site pharmacists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality assurance monitoring
Number of subjects: 0
Study: 24174321

Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA) with Impella 2.5
Number of subjects: 448

Group type: COMPARATOR
Intervention: Rotational Atherectomy (RA) with IABP
Number of subjects: 448

Group type: COMPARATOR
Intervention: No Rotational Atherectomy (RA) with Impella
Number of subjects: 448

Group type: COMPARATOR
Intervention: No Rotational Atherectomy (RA) with IABP
Number of subjects: 448
Study: 23206459

Group type: EXPERIMENTAL
Intervention: Oral prolonged-release oxycodone/naloxone (OXN PR)
Number of subjects: 0
Study: 20937657

Group type: EXPERIMENTAL
Intervention: LP/HGI
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: HP/LGI
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: LP/LGI
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: HP/HGI
Number of subjects: 827

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 827
Study: 18780534

Group type: EXPERIMENTAL
Intervention: Stabilization appliance (S group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Prefabricated occlusal appliance (R group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Both groups (S and R)
Number of subjects: 65
Study: 16203271

Group type: EXPERIMENTAL
Intervention: Capecitabine/docetaxel combination therapy
Number of subjects: 511

Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 511
Study: 11857049

Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation (1.3 g/100 g ground flaxseed and 5 g/100 g flaxseed oil)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control diet (non-supplemented foods)
Number of subjects: 80
Study: 10439881

Group type: EXPERIMENTAL
Intervention: Low-dose glucose-insulin-potassium (GIK)
Number of subjects: 954
Study: 8590846

Group type: EXPERIMENTAL
Intervention: rhG-CSF (5 micrograms/kg/day for 5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CHOP alone (control group)
Number of subjects: 14
Study: 2501313

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate as Isotard Forte
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate as Cordil-40 SR
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29802320

Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing (MPS) genetic testing
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care genetic testing
Number of subjects: 122
Study: 28219959

Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 30
Study: 25199856

Group type: EXPERIMENTAL
Intervention: Dietary NO3(‐) intake (140 mL of concentrated beetroot juice containing 11.2 mmol of NO3(‐))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (140 mL of beetroot juice devoid of NO3(‐))
Number of subjects: 12
Study: 23726325

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric toothbrush with a specially designed orthodontic brush head (Oral-B Triumph, OD17)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric toothbrush with a regular brush head (EB25)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Regular manual toothbrush (American Dental Association)
Number of subjects: 46
Study: 22011515

Group type: EXPERIMENTAL
Intervention: Mini-HLM
Number of subjects: 76

Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 76
Study: 18280971

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide [Ca(OH)2]
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single Bond adhesive system (SBAS)
Number of subjects: 0
Study: 17146025

Group type: COMPARATOR
Intervention: Health plan-based lifestyle intervention (bimonthly group meetings, quarterly coaching telephone calls, and weekly self-monitoring)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health plan-based lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12750437

Group type: EXPERIMENTAL
Intervention: Oral valacyclovir administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral acyclovir administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10773130

Group type: EXPERIMENTAL
Intervention: Polyglactin 910 suture
Number of subjects: 340

Group type: COMPARATOR
Intervention: Polydioxanone loop suture
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Both sutures
Number of subjects: 340
Study: 8813775

Group type: EXPERIMENTAL
Intervention: Peak TNF-alpha secretion in patients with systemic complications
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peak IL-6 secretion in patients with systemic complications
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peak IL-8 secretion in patients with systemic complications
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peak IL-1 beta secretion
Number of subjects: 26
Study: 1349450

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-blockade)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3909500

Group type: EXPERIMENTAL
Intervention: Vitamin E 300 mg daily for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E 600 mg daily for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atherogenic diet with 100 mg vitamin E daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31852697

Group type: EXPERIMENTAL
Intervention: Informed Health Choices podcast
Number of subjects: 84
Study: 29365382

Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids combined with inhaled steroid (Budesonide suspension 1.0 mg for inhalation, oxygen-driven atomizing inhalation, every 30 minutes, 2 times in a row, then every 12 hours)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Systemic glucocorticoids (Dexamethasone injection 0.3‐0.5 mg/kg for 1‐3 days)
Number of subjects: 78
Study: 26662710

Group type: EXPERIMENTAL
Intervention: Classic Ketogenic Diet (KD)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Modified Atkins Diet (MAD)
Number of subjects: 104
Study: 25359002

Group type: EXPERIMENTAL
Intervention: Tornado program (accelerated-track diagnosis and treatment planning, psychoeducation, pharmacological treatment by primary care physicians)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 90
Study: 22616062

Group type: EXPERIMENTAL
Intervention: Ceramic material titanium niobium oxynitride ([Ti,Nb]ON) with plasma‐chemical oxidation treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metal surfaces (titanium-tantalum alloy and tantalum)
Number of subjects: 6
Study: 20736206

Group type: EXPERIMENTAL
Intervention: Overlapping bare metal stents (BMS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overlapping drug-eluting stents (DES)
Number of subjects: 71
Study: 18359501

Group type: EXPERIMENTAL
Intervention: Tracking four objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tracking multiple objects
Number of subjects: 0
Study: 15610953

Group type: EXPERIMENTAL
Intervention: Topiramate plus risperidone (TPMG)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Divalproex plus risperidone (DVPG)
Number of subjects: 74
Study: 11986913

Group type: EXPERIMENTAL
Intervention: Regular nimodipine 30 mg every 6 h
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nimodipine AP 120 mg every 24 h
Number of subjects: 19
Study: 10440432

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 258

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 258
Study: 7486485

Group type: EXPERIMENTAL
Intervention: Fish oil (eicosapentaenoic and docosahexaenoic acids), 4 g/d
Number of subjects: 78

Group type: COMPARATOR
Intervention: Corn oil placebo, 4 g/d
Number of subjects: 78
Study: 12283375

Group type: EXPERIMENTAL
Intervention: Filshie Mark VI clips
Number of subjects: 289

Group type: COMPARATOR
Intervention: Hulka-Clemens clips
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 289
Study: 453056

Group type: EXPERIMENTAL
Intervention: Nitrogen intake of about 280 mg N/kg per day (mixed animal and plant protein sources) for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nitrogen intake of about 90 mg N/kg per day (egg protein) for 11 weeks
Number of subjects: 21
Study: 31605197

Group type: EXPERIMENTAL
Intervention: 10 g inulin plus 10 g resistant maltodextrin
Number of subjects: 116

Group type: COMPARATOR
Intervention: 20 g placebo supplementation
Number of subjects: 116
Study: 31290566

Group type: EXPERIMENTAL
Intervention: Regorafenib with no/nonsignificant gastrectomy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Regorafenib with major gastrectomy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Regorafenib pharmacokinetics in major gastrectomy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Regorafenib pharmacokinetics in no/nonsignificant gastrectomy
Number of subjects: 133
Study: 27508295

Group type: COMPARATOR
Intervention: Serum IGF-1 levels in SGA infants (27.6 ± 17.7 ng/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aortic strain in SGA infants (10.2 ± 3.1%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aortic distensibility in SGA infants (0.73 ± 0.19 cm2/dyn × 10‐4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blood pressure in SGA infants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aortic intima-media thickness (aIMT) in relation to body weight in SGA infants (383 ± 163 μm/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aortic stiffness index in relation to body weight in SGA infants (2.0 ± 1.7)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Arterial pressure-strain elastic modulus in SGA infants (293 ± 72 mm Hg)
Number of subjects: 40
Study: 25172025

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combined treatment (tDCS and sertraline)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (sham control)
Number of subjects: 73
Study: 24136883

Group type: COMPARATOR
Intervention: Chemotherapy without bevacizumab
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Chemotherapy with bevacizumab
Number of subjects: 663
Study: 22145775

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing Enteromorpha linza extract
Number of subjects: 55

Group type: COMPARATOR
Intervention: Listerine (positive control)
Number of subjects: 55
Study: 18951992

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin-B (L‐AmB)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 16082155

Group type: EXPERIMENTAL
Intervention: Prostaglandin I(2) (PGI(2)), norepinephrine and dopamine (PGI(2) group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nitroglycerin, norepinephrine and dopamine (control group)
Number of subjects: 68
Study: 12383322

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236
Study: 10089262

Group type: EXPERIMENTAL
Intervention: Exercise during hemodialysis (3 times a week, gradually increasing to 45 minutes at 60% to 80% maximal heart rate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exercise during hemodialysis
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sedentary (non-exercising)
Number of subjects: 11
Study: 7591755

Group type: EXPERIMENTAL
Intervention: Full hospital cost accounting model for surgery and anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective multicenter economic clinical trial
Number of subjects: 0
Study: 2262461

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 250 mg oral doses
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 434096

Group type: EXPERIMENTAL
Intervention: Sucrose gradient purified vaccine
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Genetron purified vaccine
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 30953522

Group type: EXPERIMENTAL
Intervention: Four-week ketogenic diet (KD)
Number of subjects: 22
Study: 28371230

Group type: EXPERIMENTAL
Intervention: Intervention involving family caregivers (FC) with seven planned encounters over 3 days, each including a 30-min visit at the patient's bedside.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 30
Study: 26081597

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment
Number of subjects: 240
Study: 23404064

Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopamine receptor agonist)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21367927

Group type: EXPERIMENTAL
Intervention: TPD 20 μg daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 20396750

Group type: EXPERIMENTAL
Intervention: Afobazole (30-60 mg/day for 1 month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16934392

Group type: EXPERIMENTAL
Intervention: PSA-based screening (biennial testing)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control group (no PSA screening)
Number of subjects: 20000
Study: 15592551

Group type: COMPARATOR
Intervention: Audit and Feedback (A and F)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Computer Aided Learning (CAL)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Guideline and Postgraduate Education Course (PGEC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A and F) and Computer Aided Learning (CAL)
Number of subjects: 63
Study: 11331253

Group type: EXPERIMENTAL
Intervention: phVEGF‐2 (200 microgram total dose, 6 injections of 6.0 mL)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (mock procedure)
Number of subjects: 6
Study: 9927915

Group type: EXPERIMENTAL
Intervention: Preventive program for mothers and children starting during pregnancy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (children from various kindergartens)
Number of subjects: 86
Study: 7993958

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.5 mg/kg orally)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3053312

Group type: EXPERIMENTAL
Intervention: Low-dose antacid regimen (1 tablet q.i.d.; acid-neutralizing capacity, 120 mmol/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cimetidine (800 mg nocte)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-dose antacid regimen
Number of subjects: 150
Study: 30373502

Group type: EXPERIMENTAL
Intervention: Mobility Feedback Device (MFD) used weekly for 6 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 86
Study: 29267990

Group type: EXPERIMENTAL
Intervention: Right unilateral electroconvulsive therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Algorithm-based pharmacologic treatment
Number of subjects: 73
Study: 28566029

Group type: EXPERIMENTAL
Intervention: Trainers' competence in delivery of the program
Number of subjects: 764

Group type: COMPARATOR
Intervention: Trainers' adherence to program content
Number of subjects: 764
Study: 26432772

Group type: EXPERIMENTAL
Intervention: Chlorella supplement (4 tablets, total chlorophyll ≈8.3 mg/tablet, three times a day for 2 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorella supplement
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24448936

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg)
Number of subjects: 1193
Study: 21399681

Group type: COMPARATOR
Intervention: Genital herpes suppression intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Baseline viral load
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Time on study
Number of subjects: 151
Study: 19034737

Group type: EXPERIMENTAL
Intervention: Naltrexone at 150 mg/day
Number of subjects: 0
Study: 15161060

Group type: EXPERIMENTAL
Intervention: aprotinin + leukofiltration
Number of subjects: 90

Group type: COMPARATOR
Intervention: aprotinin alone
Number of subjects: 90
Study: 11207640

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) at 3 IU/(m(2) body surface.day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) at 6 IU/(m(2) body surface.day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH)
Number of subjects: 78
Study: 9628422

Group type: EXPERIMENTAL
Intervention: Reaching to grasp a target in the presence of an obstacle (nontarget object)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obstacle interpretation of nontarget objects
Number of subjects: 0
Study: 7989081

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily, adjusted to 10 mg once daily if necessary after 2 weeks
Number of subjects: 20
Study: 2460421

Group type: EXPERIMENTAL
Intervention: Patient education programs presented at three critical points: Pretreatment, Treatment Week 2, and Final Treatment Week.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Patient education programs with pretest and posttest assessments.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Final Treatment Week program with pretest.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patient education programs overall.
Number of subjects: 72
Study: 29724194

Group type: EXPERIMENTAL
Intervention: Comprehensive package of interventions for maternal and neonatal health promotion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (comparison clusters)
Number of subjects: 30
Study: 27380862

Group type: EXPERIMENTAL
Intervention: 20% glycolic acid peel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15% lactic acid peel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: topical 20% vitamin C
Number of subjects: 90
Study: 24821582

Group type: EXPERIMENTAL
Intervention: Sunitinib 50mg (4 weeks on, 2 weeks off)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 86
Study: 22532941

Group type: EXPERIMENTAL
Intervention: AdheSE One with Tetric Evo Ceram and flowable composite (group TF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: AdheSE One with Tetric Evo Ceram without flowable composite (group T)
Number of subjects: 50
Study: 21303745

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg every 8 hours
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Levofloxacin 250 mg every 24 hours
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Doripenem in levofloxacin-resistant E. coli infections
Number of subjects: 1171
Study: 19023827

Group type: EXPERIMENTAL
Intervention: Test cigarettes with activated carbon filters (comparable tar levels)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional cigarettes (6-mg or 11-mg FTC tar product)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Stop smoking
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Test cigarettes with activated carbon filters
Number of subjects: 160
Study: 15981488

Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (not treated eye)
Number of subjects: 72
Study: 11375812

Group type: EXPERIMENTAL
Intervention: HES 450/0.7‐0.8
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HES 200/0.6‐0.66
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HES 70/0.5‐0.55
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HES 130/0.38‐0.45
Number of subjects: 50
Study: 9552785

Group type: EXPERIMENTAL
Intervention: Epidural saline 10 mL at 5 minutes after spinal injection (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural saline 10 mL at 20 minutes after spinal injection (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural saline 10 mL at 7 minutes after spinal injection (group D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 10 mL at 7 minutes after spinal injection (group E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No epidural injection (group F)
Number of subjects: 30
Study: 7844481

Group type: EXPERIMENTAL
Intervention: Phonological-processing intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study: 3395540

Group type: EXPERIMENTAL
Intervention: Water 100 ml administered 2 hours before operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fasted group (control)
Number of subjects: 50
Study: 31553119

Group type: EXPERIMENTAL
Intervention: 45% mandelic acid (MA) peel
Number of subjects: 50

Group type: COMPARATOR
Intervention: 30% salicylic acid (SA) peel
Number of subjects: 50
Study: 30896629

Group type: EXPERIMENTAL
Intervention: Povidone-iodine suppository
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no povidone-iodine suppository)
Number of subjects: 250
Study: 28177167

Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg/kg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 25488965

Group type: EXPERIMENTAL
Intervention: Treatment at high-accruing centers (HHACs)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Treatment at historically low-accruing centers (HLACs)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Treatment at HLACs with radiotherapy compliance adjustment
Number of subjects: 471
Study: 23963895

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study: 21318932

Group type: EXPERIMENTAL
Intervention: Integrated group prenatal care intervention (CenteringPregnancy Plus, CP+)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Standard individual care
Number of subjects: 1047